<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39372675</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1177-8881</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Drug design, development and therapy</Title><ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation></Journal><ArticleTitle>Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics.</ArticleTitle><Pagination><StartPage>4387</StartPage><EndPage>4399</EndPage><MedlinePgn>4387-4399</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S484897</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Bacterial lysates are known for having immunomodulatory properties and have been used mainly for the prevention and treatment of respiratory tract infections (RTIs). However, rigorous studies are needed to confirm the clinical efficacy of bacterial lysates with various bacterial antigen components, preparation methods, administration routes and course of treatment. OM-85, an oral standardized lysate prepared by alkaline lysis of 21 strains from 8 species of common respiratory tract pathogens, is indicated as immunotherapy for prevention of recurrent RTIs and acute infectious exacerbations of chronic bronchitis. OM-85 acts on multiple innate and adaptive immune targets and can restore type 1 helper T (Th1)/Th2 balance. Sporadic studies have shown advances in pharmacology and therapeutics of OM-85, and thus an update review is necessary.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Literature was retrieved by searching PubMed, Web of science, Embase, CNKI, and Full Text Database of Chinese Medical Journals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">New roles of OM-85 were discovered in prevention and treatment of lung cancer, pulmonary tuberculosis, SARS-CoV-2 infection, allergic rhinitis, pulmonary fibrosis, atopic dermatitis, and nephrotic syndrome. Pharmacoeconomic values of OM-85 were demonstrated in prophylaxis and treatment of RTIs, chronic obstructive pulmonary disease, asthma, chronic bronchitis, rhinosinusitis and allergic rhinitis. Two consecutive courses of OM-85 (6 or 12 months apart) could prevent recurrent RTIs in children. Maternal OM-85 treatment could offer benefits for offspring. Product-specific response was observed. The efficacy of OM-85 may be associated with patient's characteristics (eg, severity of the disease, age, immune response pattern, malignancy risk stratification).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">OM-85 can improve effectiveness of standard care for some primary diseases, and carry significant pharmacoeconomic implications. The benefits shown by OM-85 in vitro and in vivo, when extrapolated to humans, are exciting but also require caution. Individualized treatment may need to be considered. It is necessary to compare the efficacy and safety of various bacterial lysate preparations.</AbstractText><CopyrightInformation>© 2024 Zhu et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ling-Ling</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>VIP Geriatric Ward, Division of Nursing, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan-Hong</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Jian-Hua</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-3314-0451</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Des Devel Ther</MedlineTA><NlmUniqueID>101475745</NlmUniqueID><ISSNLinking>1177-8881</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C030259">Broncho-Vaxom</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002457">Cell Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000095983">Bacterial Lysates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002457" MajorTopicYN="N">Cell Extracts</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095983" MajorTopicYN="N">Bacterial Lysates</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">airway inflammatory disease</Keyword><Keyword MajorTopicYN="N">allergic diseases</Keyword><Keyword MajorTopicYN="N">bacterial lysates</Keyword><Keyword MajorTopicYN="N">immunomodulator, OM-85</Keyword><Keyword MajorTopicYN="N">pharmacoeconomic evaluation</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39372675</ArticleId><ArticleId IdType="pmc">PMC11453140</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S484897</ArticleId><ArticleId IdType="pii">484897</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaczynska A, Klosinska M, Janeczek K, Zarobkiewicz M, Emeryk A. Promising immunomodulatory effects of bacterial lysates in allergic diseases. Front Immunol. 2022;13:907149. doi:10.3389/fimmu.2022.907149</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.907149</ArticleId><ArticleId IdType="pmc">PMC9257936</ArticleId><ArticleId IdType="pubmed">35812388</ArticleId></ArticleIdList></Reference><Reference><Citation>Marseglia GL, Benazzo M, Biasci P, et al. OM-85 in the prevention of respiratory infections: state-of-The-art and future perspectives in clinical practice. J Biol Regul Homeost Agents. 2021;35:847–863. doi:10.23812/21-147-A</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/21-147-A</ArticleId><ArticleId IdType="pubmed">34155874</ArticleId></ArticleIdList></Reference><Reference><Citation>MINAPHARM Pharmaceuticals. Product In-Details for Broncho-vaxom. Available from: https://www.minapharm.com/_handler/DownloadHandler.ashx?n=349.pdf&amp;f=Attach&amp;fileName=Broncho-vaxom.pdf. Accessed May
2, 2024.</Citation></Reference><Reference><Citation>Sun M, Xie L, Zhou J, et al. EP07.04-17 Study on the regulatory mechanism of OM-85 BV on the immune microenvironment of clinical early-stage lung adenocarcinoma. J Thorac Oncol. 2023;18:S551. doi:10.1016/j.jtho.2023.09.1030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2023.09.1030</ArticleId></ArticleIdList></Reference><Reference><Citation>Recchia F, Candeloro G, Cesta A, et al. Maintenance immunotherapy following carboplatin (CBDCA)-pemetrexed (PEM) chemotherapy in advanced adenocarcinoma (ADK) of the lung: a Phase II study. Cancer Res. 2013;73:480. doi:10.1158/1538-7445.AM2013-480</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2013-480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y, Zhang Y, Tian H, et al. EP07.02-01 Evaluation of the efficacy of oral bacterial lysates in patients with high-risk lung nodules detected by CT screening. J Thorac Oncol. 2023;18:S523. doi:10.1016/j.jtho.2023.09.980</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2023.09.980</ArticleId></ArticleIdList></Reference><Reference><Citation>McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369(10):910–919. doi:10.1056/NEJMoa1214726</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1214726</ArticleId><ArticleId IdType="pmc">PMC3951177</ArticleId><ArticleId IdType="pubmed">24004118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai QS, Zhu M, Chen YY, Xia Q, Sun YP. Study on the effect of short course chemotherapy combined with broncho-vaxom on the prognosis of new smear positive pulmonary tuberculosis patients. Chin J Prim Med Pharm. 2018;25:87–91. doi:10.3760/cma.j.issn.1008-6706.2018.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1008-6706.2018.01.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Abate G, Hoft DF. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther. 2016;5:37–45. doi:10.2147/ITT.S81892</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ITT.S81892</ArticleId><ArticleId IdType="pmc">PMC4970630</ArticleId><ArticleId IdType="pubmed">27529060</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhvaryu M, Vakharia B. Drug-resistant tuberculosis: emerging treatment options. Clin Pharmacol. 2011;3:51–67. doi:10.2147/CPAA.S11597</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CPAA.S11597</ArticleId><ArticleId IdType="pmc">PMC3262386</ArticleId><ArticleId IdType="pubmed">22287857</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Zhou L, Tamm M, Roth M. OM-85 Broncho-Vaxom®, a bacterial lysate, reduces SARS-CoV-2 binding proteins on human bronchial epithelial cells. Biomedicines. 2021;9:1544. doi:10.3390/biomedicines9111544</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9111544</ArticleId><ArticleId IdType="pmc">PMC8615539</ArticleId><ArticleId IdType="pubmed">34829773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivniouk V, Pivniouk O, DeVries A, et al. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression. J Allergy Clin Immunol. 2022;149:923–933.e6. doi:10.1016/j.jaci.2021.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.11.019</ArticleId><ArticleId IdType="pmc">PMC8660661</ArticleId><ArticleId IdType="pubmed">34902435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassão G, Antunes KH, Gonçalvez JIB, et al. OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients. bioRxiv. 2022. doi:10.1101/2022.07.29.502045</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.07.29.502045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gareri P, Trevisan C, Abbatecola AM, Malara A, Incalzi RA. Efficacy of OM-85 in recurrent respiratory tract infections. Rev Recent Clin Trials. 2023;18:223–227. doi:10.2174/1574887118666230518112806</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574887118666230518112806</ArticleId><ArticleId IdType="pubmed">37202893</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L, Zheng CP, Sun YQ, Xu G, Wen W, Fu QL. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy. 2014;28:110–116. doi:10.2500/ajra.2013.27.4021</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/ajra.2013.27.4021</ArticleId><ArticleId IdType="pubmed">24717947</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Q, Li P, Li Y, et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa. Rhinology. 2019;57(6):451–459. doi:10.4193/Rhin19.161</Citation><ArticleIdList><ArticleId IdType="doi">10.4193/Rhin19.161</ArticleId><ArticleId IdType="pubmed">31403136</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeczek K, Emeryk A, Rachel M, Duma D, Zimmer Ł, Poleszak E. Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen-induced allergic rhinitis in children: a randomized controlled trial. J Allergy Clin Immunol Pract. 2021;9(1):453–462. doi:10.1016/j.jaip.2020.08.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2020.08.025</ArticleId><ArticleId IdType="pubmed">32858239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Yuan S, Zheng X, Wang X, Zhang J. Pre-exposure to aerosolized polyvalent bacterial lysates protects against bleomycin-induced pulmonary fibrosis in mice. Inflammation. 2022;45(4):1692–1699. doi:10.1007/s10753-022-01653-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-022-01653-w</ArticleId><ArticleId IdType="pubmed">35249190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodemer C, Guillet G, Cambazard F, et al. Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: a randomized study. PLoS One. 2017;12:e0161555. doi:10.1371/journal.pone.0161555</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0161555</ArticleId><ArticleId IdType="pmc">PMC5363804</ArticleId><ArticleId IdType="pubmed">28333952</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the treatment of atopic dermatitis. Immunotargets Ther. 2020;9:151–156. doi:10.2147/ITT.S260370</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ITT.S260370</ArticleId><ArticleId IdType="pmc">PMC7532907</ArticleId><ArticleId IdType="pubmed">33062619</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis. Immunotargets Ther. 2020;9:255–272. doi:10.2147/ITT.S229667</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ITT.S229667</ArticleId><ArticleId IdType="pmc">PMC7667501</ArticleId><ArticleId IdType="pubmed">33204661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge L, Yu L, Yu SY, Lu W. Clinical observation of OM- 85 BV in preventing frequently relapsing nephrotic syndrome in children. Guangdong Med J. 2016;37(8):1214–1217. doi:10.13820/j.cnki.gdyx.20160429.007</Citation><ArticleIdList><ArticleId IdType="doi">10.13820/j.cnki.gdyx.20160429.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HD. Bacterial lysis product in improvement of immune function in children with steroid-dependent nephrotic syndrome. Int Med Health Guid News. 2018;24(14):2114–2117. doi:10.3760/cma.j.issn.1007-1245.2018.14.017</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1007-1245.2018.14.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Buendía JA, Patiño DG, Lindarte EF. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis. BMC Pulm Med. 2022;22:465. doi:10.1186/s12890-022-02264-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-022-02264-9</ArticleId><ArticleId IdType="pmc">PMC9724379</ArticleId><ArticleId IdType="pubmed">36474205</ArticleId></ArticleIdList></Reference><Reference><Citation>Berber A, Del-Rio-Navarro BE. Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections (ARTIs) in children that attend day-care centers. Health Econ Rev. 2019;9:12. doi:10.1186/s13561-019-0230-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13561-019-0230-1</ArticleId><ArticleId IdType="pmc">PMC6734393</ArticleId><ArticleId IdType="pubmed">31065886</ArticleId></ArticleIdList></Reference><Reference><Citation>Koatz AM, Zakin L, Ciceran A. Cost consequence of preventive treatment with OM 85 bacterial lysate compared to the same patients without OM 85 the previous year in allergic rhinitis, asthma and COPD in Argentina. Value Health. 2015;18:A498. doi:10.1016/j.jval.2015.09.1400</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.09.1400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravasio R. Economic analysis of the immunostimulant OM-85 for the prevention of paediatric recurrent upper respiratory tract infections. Glob Reg Health Technol Asse. 2015;2:135–142.</Citation></Reference><Reference><Citation>Troiano G, Messina G, Nante N. Bacterial lysates (OM-85 BV): a cost-effective proposal in order to contrast antibiotic resistance. J Prev Med Hyg. 2021;62:E564–E573. doi:10.15167/2421-4248/jpmh2021.62.2.1734</Citation><ArticleIdList><ArticleId IdType="doi">10.15167/2421-4248/jpmh2021.62.2.1734</ArticleId><ArticleId IdType="pmc">PMC8451348</ArticleId><ArticleId IdType="pubmed">34604601</ArticleId></ArticleIdList></Reference><Reference><Citation>Xuan J, Wang L, Yin H, Xuan D, Zhou Y, Hu S. The cost-effectiveness of OM-85 in managing respiratory tract infections in China. J Med Econ. 2015;18:167–172. doi:10.3111/13696998.2014.971159</Citation><ArticleIdList><ArticleId IdType="doi">10.3111/13696998.2014.971159</ArticleId><ArticleId IdType="pubmed">25275426</ArticleId></ArticleIdList></Reference><Reference><Citation>Xuan J, Wang L, Xuan D, Zhou Y, Hu S. Evaluation of cost effectiveness of OM-85 in China. Value Health. 2014;17:A779. doi:10.1016/j.jval.2014.08.366</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2014.08.366</ArticleId><ArticleId IdType="pubmed">27202888</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Fang Z, Saborío GP, Xiu Q. Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung. 2015;193:513–519. doi:10.1007/s00408-015-9737-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-015-9737-3</ArticleId><ArticleId IdType="pubmed">26044556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutiérrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest. 2001;119:1742–1748. doi:10.1378/chest.119.6.1742</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.119.6.1742</ArticleId><ArticleId IdType="pubmed">11399700</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Bianchini S, Polinori I, Principi N. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: a retrospective study. Int J Environ Res Public Health. 2019;16:1065. doi:10.3390/ijerph16061065</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph16061065</ArticleId><ArticleId IdType="pmc">PMC6466214</ArticleId><ArticleId IdType="pubmed">30934539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mincham KT, Scott NM, Lauzon-Joset JF, et al. Maternal immunomodulation as a strategy to protect offspring against asthma. Eur J Immunol. 2018;48(1):64–65.</Citation></Reference><Reference><Citation>Mincham KT, Jones AC, Bodinier M, et al. Transplacental innate immune training via maternal microbial exposure: role of XBP1-ERN1 axis in dendritic cell precursor programming. Front Immunol. 2020;11:601494. doi:10.3389/fimmu.2020.601494</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.601494</ArticleId><ArticleId IdType="pmc">PMC7793790</ArticleId><ArticleId IdType="pubmed">33424847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauzon-Joset JF, Mincham KT, Scott NM, et al. Protection against neonatal respiratory viral infection via maternal treatment during pregnancy with the benign immune training agent OM-85. Clin Transl Immunology. 2021;10:e1303. doi:10.1002/cti2.1303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1303</ArticleId><ArticleId IdType="pmc">PMC8248556</ArticleId><ArticleId IdType="pubmed">34249358</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Marchisio P, Prada E, et al. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014;32:2546–2552. doi:10.1016/j.vaccine.2014.03.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.055</ArticleId><ArticleId IdType="pubmed">24681270</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh TL, Shih PC, Liu SJ, et al. The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:217–230. doi:10.2147/DDDT.S155110</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S155110</ArticleId><ArticleId IdType="pmc">PMC5790137</ArticleId><ArticleId IdType="pubmed">29416317</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth M, Khameneh HJ, Fang L, Tamm M, Rossi GA. Distinct antiviral properties of two different bacterial lysates. Can Respir J. 2021;2021:8826645. doi:10.1155/2021/8826645</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8826645</ArticleId><ArticleId IdType="pmc">PMC7878088</ArticleId><ArticleId IdType="pubmed">33613792</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzimenti C, D’Agostino A, Pirrello P, Ruiba A, Melioli G. The SARS-CoV-2 cellular receptor ACE2 is expressed in oropharyngeal cells and is modulated in vitro by the bacterial lysate Lantigen B. bioRxiv. 2022. doi:10.1101/2022.05.06.490962</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.06.490962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara F, Rial A, Suárez N, Chabalgoity JA. Polyvalent bacterial lysate protects against pneumonia independently of neutrophils, IL-17A or Caspase-1 activation. Front Immunol. 2021;12:562244. doi:10.3389/fimmu.2021.562244</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.562244</ArticleId><ArticleId IdType="pmc">PMC8108696</ArticleId><ArticleId IdType="pubmed">33981296</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong E, Lauzon-Joset JF, Leffler J, et al. IRF7-associated immunophenotypes have dichotomous responses to virus/allergen coexposure and OM-85-induced reprogramming. Front Immunol. 2021;12:699633. doi:10.3389/fimmu.2021.699633</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.699633</ArticleId><ArticleId IdType="pmc">PMC8339879</ArticleId><ArticleId IdType="pubmed">34367159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao S, Qin R, Song X, He L, Lin X, Li J. Bacterial lysate add-on therapy in adult and childhood asthma: a systematic review and meta-analysis. J Thorac Dis. 2023;15:3143–3157. doi:10.21037/jtd-22-1469</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd-22-1469</ArticleId><ArticleId IdType="pmc">PMC10323573</ArticleId><ArticleId IdType="pubmed">37426164</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer GM, Braunstahl GJ, van der Ploeg EK, et al. Bacterial lysate add-on therapy to reduce exacerbations in severe asthma: a double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51:1172–1184. doi:10.1111/cea.13990</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.13990</ArticleId><ArticleId IdType="pmc">PMC9292626</ArticleId><ArticleId IdType="pubmed">34289183</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Park YB, An TJ, Yoo KH, Rhee CK. Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations. BMC Pulm Med. 2023;23:378. doi:10.1186/s12890-023-02665-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-023-02665-4</ArticleId><ArticleId IdType="pmc">PMC10559651</ArticleId><ArticleId IdType="pubmed">37805515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiencke P, Viehmann K, Rychlik R. Cost-effectiveness analysis, prevention of atopic dermatitis by oral application of bacterial lysate in newborns/small children. Eur J Health Econ. 2013;14:995–1002. doi:10.1007/s10198-012-0448-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10198-012-0448-x</ArticleId><ArticleId IdType="pubmed">23242758</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>